Search Results - "Heymach, John V"

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy by Skoulidis, Ferdinandos, Heymach, John V.

“…The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for oncogene-addicted subgroups of non-small-cell lung cancer (for…”
Get full text

Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy by Patel, Sonia A, Nilsson, Monique B, Le, Xiuning, Cascone, Tina, Jain, Rakesh K, Heymach, John V

“…Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known mechanisms employed by solid tumors to recruit blood vessels…”
Get full text

A STING operation to expose KRAS and STK11 co-mutated lung cancers by Skoulidis, Ferdinandos, Heymach, John V., Cascone, Tina

“…KRAS and STK11 (LKB1) co-mutated (KL) tumors define an immunologically cold and anti-PD-(L)1-refractory non-small-cell lung cancer (NSCLC) subset. In this…”
Get full text

Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer by Pan, Kelsey, Concannon, Kyle, Li, Jing, Zhang, Jianjun, Heymach, John V., Le, Xiuning

“…The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC), largely owing to the improved control of systemic disease provided by…”
Get full text

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer by Robichaux, Jacqulyne P., Elamin, Yasir Y., Tan, Zhi, Carter, Brett W., Zhang, Shuxing, Liu, Shengwu, Li, Shuai, Chen, Ting, Poteete, Alissa, Estrada-Bernal, Adriana, Le, Anh T., Truini, Anna, Nilsson, Monique B., Sun, Huiying, Roarty, Emily, Goldberg, Sarah B., Brahmer, Julie R., Altan, Mehmet, Lu, Charles, Papadimitrakopoulou, Vassiliki, Politi, Katerina, Doebele, Robert C., Wong, Kwok-Kin, Heymach, John V.

“…Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR…”
Get full text

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC by Le, Xiuning, Puri, Sonam, Negrao, Marcelo V, Nilsson, Monique B, Robichaux, Jacqulyne, Boyle, Theresa, Hicks, J Kevin, Lovinger, Katherine L, Roarty, Emily, Rinsurongkawong, Waree, Tang, Ming, Sun, Huiying, Elamin, Yasir, Lacerda, Lara C, Lewis, Jeff, Roth, Jack A, Swisher, Stephen G, Lee, J Jack, William, Jr, William N, Glisson, Bonnie S, Zhang, Jianjun, Papadimitrakopoulou, Vassiliki A, Gray, Jhanelle E, Heymach, John V

“…Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of -mutant NSCLC…”
Get full text

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition by Mak, Milena P, Tong, Pan, Diao, Lixia, Cardnell, Robert J, Gibbons, Don L, William, William N, Skoulidis, Ferdinandos, Parra, Edwin R, Rodriguez-Canales, Jaime, Wistuba, Ignacio I, Heymach, John V, Weinstein, John N, Coombes, Kevin R, Wang, Jing, Byers, Lauren Averett

“…We previously demonstrated the association between epithelial-to-mesenchymal transition (EMT) and drug response in lung cancer using an EMT signature derived…”
Get full text

Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance by Chu, Yanshuo, Dai, Enyu, Li, Yating, Han, Guangchun, Pei, Guangsheng, Ingram, Davis R., Thakkar, Krupa, Qin, Jiang-Jiang, Dang, Minghao, Le, Xiuning, Hu, Can, Deng, Qing, Sinjab, Ansam, Gupta, Pravesh, Wang, Ruiping, Hao, Dapeng, Peng, Fuduan, Yan, Xinmiao, Liu, Yunhe, Song, Shumei, Zhang, Shaojun, Heymach, John V., Reuben, Alexandre, Elamin, Yasir Y., Pizzi, Melissa P., Lu, Yang, Lazcano, Rossana, Hu, Jian, Li, Mingyao, Curran, Michael, Futreal, Andrew, Maitra, Anirban, Jazaeri, Amir A., Ajani, Jaffer A., Swanton, Charles, Cheng, Xiang-Dong, Abbas, Hussein A., Gillison, Maura, Bhat, Krishna, Lazar, Alexander J., Green, Michael, Litchfield, Kevin, Kadara, Humam, Yee, Cassian, Wang, Linghua

“…Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states remain to be fully characterized. Here we present a single-cell…”
Get full text

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing by Zhang, Jianjun, Fujimoto, Junya, Zhang, Jianhua, Wedge, David C., Song, Xingzhi, Zhang, Jiexin, Seth, Sahil, Chow, Chi-Wan, Cao, Yu, Gumbs, Curtis, Gold, Kathryn A., Kalhor, Neda, Little, Latasha, Mahadeshwar, Harshad, Moran, Cesar, Protopopov, Alexei, Sun, Huandong, Tang, Jiabin, Wu, Xifeng, Ye, Yuanqing, William, William N., Lee, J. Jack, Heymach, John V., Hong, Waun Ki, Swisher, Stephen, Wistuba, Ignacio I., Futreal, P. Andrew

“…Cancers are composed of populations of cells with distinct molecular and phenotypic features, a phenomenon termed intratumor heterogeneity (ITH). ITH in lung…”
Get full text

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer by Liao, Zhongxing, Lee, J Jack, Komaki, Ritsuko, Gomez, Daniel R, O'Reilly, Michael S, Fossella, Frank V, Blumenschein, Jr, George R, Heymach, John V, Vaporciyan, Ara A, Swisher, Stephen G, Allen, Pamela K, Choi, Noah Chan, DeLaney, Thomas F, Hahn, Stephen M, Cox, James D, Lu, Charles S, Mohan, Radhe

“…Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with…”
Get full text

Antibody-drug conjugates in lung cancer: dawn of a new era? by Coleman, Niamh, Yap, Timothy A., Heymach, John V., Meric-Bernstam, Funda, Le, Xiuning

“…Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in modern drug development. By harnessing the powers of both cytotoxic…”
Get full text

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer by Schvartsman, Gustavo, Peng, S. Andrew, Bis, Giorgios, Lee, J. Jack, Benveniste, Marcelo F.K., Zhang, Jianjun, Roarty, Emily B., Lacerda, Lara, Swisher, Stephen, Heymach, John V., Fossella, Frank V., William, William N.

“…•In NSCLC, overall response rate to single-agent chemotherapy after anti-PD1 failure was 39%.•Eleven out of 28 patients achieved a response (8 confirmed, 3…”
Get full text

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer by Sen, Triparna, Tong, Pan, Diao, Lixia, Li, Lerong, Fan, Youhong, Hoff, Jennifer, Heymach, John V, Wang, Jing, Byers, Lauren Averett

“…Drugs targeting DNA repair and cell-cycle checkpoints have emerged as promising therapies for small-cell lung cancer (SCLC). Among these, the WEE1 inhibitor…”
Get full text

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells by Chen, Pei-Hsuan, Cai, Ling, Huffman, Kenneth, Yang, Chendong, Kim, Jiyeon, Faubert, Brandon, Boroughs, Lindsey, Ko, Bookyung, Sudderth, Jessica, McMillan, Elizabeth A., Girard, Luc, Chen, Dong, Peyton, Michael, Shields, Misty D., Yao, Bo, Shames, David S., Kim, Hyun Seok, Timmons, Brenda, Sekine, Ikuo, Britt, Rebecca, Weber, Stephanie, Byers, Lauren A., Heymach, John V., Chen, Jing, White, Michael A., Minna, John D., Xiao, Guanghua, DeBerardinis, Ralph J.

“…Intermediary metabolism in cancer cells is regulated by diverse cell-autonomous processes, including signal transduction and gene expression patterns, arising…”
Get full text

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer by CARDNELL, Robert J, YING FENG, BYERS, Lauren A, LIXIA DIAO, FAN, You-Hong, MASRORPOUR, Fatemah, JING WANG, YUQIAO SHEN, MILLS, Gordon B, MINNA, John D, HEYMACH, John V

“…Small cell lung carcinoma (SCLC) is an aggressive malignancy affecting nearly 30,000 people annually in the United States. We have previously identified…”
Get full text

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer by Nong, Jingying, Gong, Yuhua, Guan, Yanfang, Yi, Xin, Yi, Yuting, Chang, Lianpeng, Yang, Ling, Lv, Jialin, Guo, Zhirong, Jia, Hongyan, Chu, Yuxing, Liu, Tao, Chen, Ming, Byers, Lauren, Roarty, Emily, Lam, Vincent K., Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio, Heymach, John V., Glisson, Bonnie, Liao, Zhongxing, Lee, J. Jack, Futreal, P. Andrew, Zhang, Shucai, Xia, Xuefeng, Zhang, Jianjun, Wang, Jinghui

“…Subclonal architecture and genomic evolution of small-cell lung cancer (SCLC) under treatment has not been well studied primarily due to lack of tumor…”
Get full text

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells by Kim, Jiyeon, Hu, Zeping, Cai, Ling, Li, Kailong, Choi, Eunhee, Faubert, Brandon, Bezwada, Divya, Rodriguez-Canales, Jaime, Villalobos, Pamela, Lin, Yu-Fen, Ni, Min, Huffman, Kenneth E., Girard, Luc, Byers, Lauren A., Unsal-Kacmaz, Keziban, Peña, Christopher G., Heymach, John V., Wauters, Els, Vansteenkiste, Johan, Castrillon, Diego H., Chen, Benjamin P. C., Wistuba, Ignacio, Lambrechts, Diether, Xu, Jian, Minna, John D., DeBerardinis, Ralph J.

“…In human cell lines with mutant KRAS and loss of LKB1, CPS1 expression correlates inversely with LKB1 expression; silencing CPS1 in these cells induces DNA…”
Get full text

Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets by Ferrarotto, Renata, Mitani, Yoshitsugu, McGrail, Daniel J, Li, Kaiyi, Karpinets, Tatiana V, Bell, Diana, Frank, Steven J, Song, Xingzhi, Kupferman, Michael E, Liu, Bin, Lee, J Jack, Glisson, Bonnie S, Zhang, Jianhua, Aster, Jon C, Lin, Shiaw-Yih, Futreal, P Andrew, Heymach, John V, El-Naggar, Adel K

“…Salivary gland adenoid cystic carcinoma (ACC) has heterogeneous clinical behavior. Currently, all patients are treated uniformly, and no standard-of-care…”
Get full text

A pan-cancer proteomic perspective on The Cancer Genome Atlas by Akbani, Rehan, Ng, Patrick Kwok Shing, Werner, Henrica M. J., Shahmoradgoli, Maria, Zhang, Fan, Ju, Zhenlin, Liu, Wenbin, Yang, Ji-Yeon, Yoshihara, Kosuke, Li, Jun, Ling, Shiyun, Seviour, Elena G., Ram, Prahlad T., Minna, John D., Diao, Lixia, Tong, Pan, Heymach, John V., Hill, Steven M., Dondelinger, Frank, Städler, Nicolas, Byers, Lauren A., Meric-Bernstam, Funda, Weinstein, John N., Broom, Bradley M., Verhaak, Roeland G. W., Liang, Han, Mukherjee, Sach, Lu, Yiling, Mills, Gordon B.

“…Protein levels and function are poorly predicted by genomic and transcriptomic analysis of patient tumours. Therefore, direct study of the functional proteome…”
Get full text

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients by Parra, Edwin R, Behrens, Carmen, Rodriguez-Canales, Jaime, Lin, Heather, Mino, Barbara, Blando, Jorge, Zhang, Jianjun, Gibbons, Don L, Heymach, John V, Sepesi, Boris, Swisher, Stephen G, Weissferdt, Annikka, Kalhor, Neda, Izzo, Julie, Kadara, Humam, Moran, Cesar, Lee, Jack J, Wistuba, Ignacio I

“…We investigated the correlation between immunohistochemical PD-L1 expression and tumor-associated immune cells (TAICs) density in non-small cell lung carcinoma…”
Get full text